

Increasing the access to affordable medicine in developing countries and LDCs: between regulation and competition

Dr Sven Gallasch
Centre for Competition Policy,
United Kingdom

Dr Mor Bakhoun
Max Planck Institute for Innovation
and Competition, Germany

Background

Developed world

- Complex interplay of IP/Competition/pharma regulations
- Brand/generic dichotomy
- Prone to regulatory gaming – pharma antitrust

Developing world

- same dichotomy not necessarily applicable
- Less prevalent interplay – to a certain extent unknown
- How to increase access to affordable medicines through regulation and competition while avoiding regulatory gaming

Project – main research objectives

1. The status quo: identifying the relevant framework
2. Identifying barrier for entry to the pharmaceutical market
3. Providing advice on the improvement of access to affordable medicine

Project – the approach

1. Data collection

Creation of panel data set through questionnaires, surveys and structured interviews

2. Empirical research

Qualitative data analysis on a country by country basis and later on comparative basis

3. Policy recommendations

min: comprehensive overview of access

max: compare and delineate individual approaches

Project – categories of variables

- Pharmaceutical regulations
 - Incl. marketing authorisation, drug price regulation, substitution laws, parallel trade
- Competition legislation
 - Incl. US/EU model, policy goals, covering regulated markets, IP exemption, enforcement level, compulsory licensing
- IP legislation
 - Incl. TRIPS, patent enforcement system (bifurcation)

Project – categories of variables (cont)

- Procurement
- Sector specific information
 - Incl. supply side, demand side (buyer power, distribution, public/private health)
- Anticompetitive conduct

Questions and suggestions?

Please contact us:

Sven Gallasch s.gallasch@uea.ac.uk

Mor Bakhoum mor.bakhoum@ip.mpg.de